Literature DB >> 11986887

Hypertension and obesity.

M E Díaz1.   

Abstract

Obesity, as defined by bodily weight (body weight) and by bodily conformation-derived variables, accompanies hypertension in many patients. Both conditions are independent cardiovascular risk factors. In a formal survey carried out in the adult general population of Uruguay (LATIR Study, 575 adult and elderly subjects of whom 41.6% were males), we found the prevalence of hypertension to be 28.5% (95% CI: 24.9-32.4%) and that 74.4% of hypertensive individuals had a body mass index (BMI) higher than 25 kg/m(2) (95% CI: 67.0-80.8%). This association between obesity and hypertension forms part of a broader relationship between body weight and blood pressure (BP). In the general population, BP bears a positive linear correlation with BMI and waist-to-hip ratio over the continuous ranges of normal and unfavourable values of these three variables (r = 0.42, P < 0.001 for the correlation between BMI and mean BP, LATIR Study). Patients who present hypertension and obesity usually present other unfavourable conditions for cardiovascular prognosis, including changes in carbohydrate and lipid metabolism, hyperuricaemia, left ventricular hypertrophy, and/or the obstructive sleep apnoea syndrome. On average, hypertension is salt-sensitive in obese patients, and plasma volume and cardiac index are increased. Adequate control of body weight results in substantial reductions in total blood volume, cardiac output, BP and left ventricular mass, and in an amelioration or the disappearance of sleep apnoea. Adequate sodium intake restriction must form part of any diet prescribed to obese hypertensive patients. Various drug classes may be used to treat hypertension efficaciously in patients who also present obesity.

Entities:  

Mesh:

Year:  2002        PMID: 11986887     DOI: 10.1038/sj.jhh.1001335

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  8 in total

1.  Adiposity indicators and blood pressure in children: nothing beyond body mass index?

Authors:  A Chiolero
Journal:  J Hum Hypertens       Date:  2014-10-23       Impact factor: 3.012

2.  Sugar-sweetened beverages and school students' hypertension in urban areas of Nanjing, China.

Authors:  Zhenzhen Qin; Fei Xu; Qing Ye; Hairong Zhou; Chao Li; Jing He; Zhiyong Wang; Xin Hong; Xiangyu Hou
Journal:  J Hum Hypertens       Date:  2018-02-06       Impact factor: 3.012

Review 3.  Obesity and hypertension in the Argentinian population compared to the white Hispanic population of the United States.

Authors:  Mónica G Díaz; Eduardo J Rusak; Erwin A Aguilar; Claudio A Bellido
Journal:  Curr Hypertens Rep       Date:  2014-07       Impact factor: 5.369

4.  Optimal cut-off values of anthropometric markers to predict hypertension in North Indian population.

Authors:  Shilpi Gupta; Satwanti Kapoor
Journal:  J Community Health       Date:  2012-04

5.  Prevalence and correlates of obesity among Lusaka residents, Zambia: a population-based survey.

Authors:  Emmanuel Rudatsikira; Adamson S Muula; David Mulenga; Seter Siziya
Journal:  Int Arch Med       Date:  2012-05-02

6.  Association of obesity with hypertension and type 2 diabetes mellitus in India: A meta-analysis of observational studies.

Authors:  Giridhara R Babu; G V S Murthy; Yamuna Ana; Prital Patel; R Deepa; Sara E Benjamin Neelon; Sanjay Kinra; K Srinath Reddy
Journal:  World J Diabetes       Date:  2018-01-15

7.  Serum concentrations of adiponectin, leptin, resistin, ghrelin and insulin and their association with obesity indices in obese normo- and hypertensive patients - pilot study.

Authors:  Mariusz Stępień; Rafał N Wlazeł; Marek Paradowski; Maciej Banach; Magdalena Rysz; Małgorzata Misztal; Jacek Rysz
Journal:  Arch Med Sci       Date:  2012-07-04       Impact factor: 3.318

8.  Triple Burden of Obesity, Undernutrition, and Cardiovascular Disease Risk among Indian Tribes.

Authors:  Gautam K Kshatriya; Subhendu K Acharya
Journal:  PLoS One       Date:  2016-01-25       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.